HTR2A and Parkinson disease: For example, changes in serotonin receptor 5HT2A expression have been implicated in the presence of visual hallucinations in Parkinson's disease, whilst the novel 5-HT2A inverse agonist, Pimavanserin, appears to be a promising treatment for these symptoms (Stahl, 2016).